| Incyte Corp | 89.43 / -0.38% |
| Date/Time | 10/26 / 16:27 |
| Chg. / Chg.(%) | -0.34 / -0.38% |
| Bid | 89.19 / 1 |
| Ask | 89.52 / 1 |
| Open | 89.85 |
| Previous Close | 89.77 |
| High | 90.15 |
| Low | 89.01 |
| Volume [USD] | 672,233.29 |
| Volume [Units] | 12,235 |
| Price fixings | 71 |
| ISIN | US45337C1027 |
| Security | INCY |
| Exchange | Cboe US |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| NASDAQ | 89.3950 |  |
171,052 |
| IEX | 89.40 | |
14,283 |
| Cboe US | 89.43 | |
12,235 |
| TradeGate | 74.850 | |
151 |
| gettex | 75.630 | |
15 |
| Frankfurt | 74.8800 |  |
0 |
| München | 75.08 | |
0 |
| Düsseldorf | 75.83 | |
0 |
| Berlin | 75.98 | |
0 |
| Lang & Schwa.. | 75.65 |  |
|
| Stuttgart | 75.770 | |
|
| Vienna Globa.. | 75.58 | |
400 |
| London Inter.. | 90.14 | 71 | |
| Mexico | 1,933.00 | |
400 |
News
- BriaCell Breast Cancer Survival Data: 13.3 Months Versus 7.2-9.8 Months
10/21/2020 / 12:30 - GlobeNewswire - Zai Lab Announces First Patient Dosed in Greater China in the Global Phase 2/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer
10/06/2020 / 13:30 - GlobeNewswire - BriaCell to Present Clinical Findings at the 2020 San Antonio Breast Cancer Symposium®, December 9 – 11
10/06/2020 / 12:30 - GlobeNewswire - Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC
10/05/2020 / 13:30 - GlobeNewswire - MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte
09/21/2020 / 13:30 - GlobeNewswire
Real-time